Ethris — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Ethris is a clinical-stage biotech specializing in mRNA therapeutics for respiratory diseases, utilizing its proprietary SNIM® RNA and LNP delivery platform. The company's lead programs target rare genetic disorders like cystic fibrosis and primary ciliary dyskinesia, with a broader pipeline exploring applications in viral defense and chronic lung diseases. As a private company, Ethris has secured significant partnerships with major pharmaceutical players like AstraZeneca and Vertex Pharmaceuticals, positioning it as a key innovator in localized mRNA delivery beyond systemic vaccines.

Respiratory DiseasesGenetic DisordersViral Infections

Technology Platform

Proprietary platform combining stabilized non-immunogenic mRNA (SNIM® RNA) with lipid nanoparticles (LNPs) formulated for targeted delivery to the respiratory tract via inhalation.

Opportunities

The validated success of mRNA vaccines creates a receptive environment for therapeutic mRNA, accelerating development and investment.

Massive unmet needs in chronic respiratory diseases like COPD and asthma represent blockbuster market potential for a successful localized therapy.

Successful proof-of-concept in the lung could enable platform expansion to other local tissues and organ systems.

Risk Factors

The core technology risk of achieving effective and durable mRNA delivery and protein expression in the human lung remains unproven.

Clinical development is high-risk, with potential for safety issues or lack of efficacy in trials.

Intense and growing competition from large pharma and well-funded biotechs in the mRNA and pulmonary delivery space threatens market position.

Competitive Landscape

Ethris operates in a highly competitive field against large mRNA leaders like Moderna and BioNTech, which are expanding into therapeutics, and specialized pulmonary delivery companies like Translate Bio (acquired by Sanofi) and ReCode Therapeutics. Its key differentiator is the specific focus on non-immunogenic mRNA and nebulized LNP formulations designed for direct-to-lung delivery, a niche with fewer established players but growing interest.

More companies in RNA Therapeutics (non-mRNA) →More companies in Germany →